Psoriasis

A majority of psoriasis patients in phase 3 clinical trials for biologics are white, says authors of a recent study. As ethnicity and race may play a role in response to biologics, researchers emphasize need for more diversity in clinical trials.

Ardon Health patients with autoimmune conditions have expressed common questions and concerns about COVID-19.

A phase 3b study investigating the efficacy and safety of risankizumab compared to secukinumab showed positive results, with risankizumab demonstrating noninferiority to secukinumab at week 16, and superiority at week 52.

The U.S. FDA has approved to expand the indication for golimumab (SIMPONI ARIA, Janssen Pharmaceutical Companies of Johnson & Johnson) to include it was a treatment for active psoriatic arthritis (PsA) in pediatric patients 2 years and older.

The latest guidelines for psoriasis from the American Academy of Dermatology and the National Psoriasis Foundation recommend physicians monitor their patients for liver disease when prescribed medication for psoriasis, such as methotrexate.

UCB announces the U.S. Food and Drug Administration and the European Medicines Agency have accepted the Biologics License Application and Marketing Authorization Application for bimekizumab for the treatment of moderate-to-severe plaque psoriasis in adults.

An overwhelming majority of subjects in phase 3 psoriasis clinical trials are Caucasian, leaving unanswered questions about how one’s ethnicity or race might impact the safety and efficacy of today’s psoriasis treatments, according to a research letter published August 7 in the British Journal of Dermatology.

Merck announces positive results from its phase 2b trial evaluating sonelokinab, an investigational anti-IL-17 A/F nanobody, in adult patients with moderate-to-severe chronic plaque psoriasis.

Color-coded and picture labeling on topical psoriasis medications improved psoriasis patients’ knowledge and understanding of how to correctly use the medications, according to a study published April 10 in the Journal of Pharmacy and BioAllied Sciences.

MC2 Therapeutics and EPI Health announce they have entered into a collaboration agreement for the commercialization of calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064% (Wynzora Cream), a newly U.S. FDA-approved topical treatment for plaque psoriasis in adults.

Dermavant announces positive results from its two identical phase 3 trials investigating tapinarof cream 1% for treatment of plaque psoriasis in adult patients.

Eli Lilly’s mirikizumab demonstrates superiority over secukinumab (Cosentyx, Novartis) as a treatment for moderate-to-severe plaque psoriasis, according to recently released results from the OASIS-2 study.

Phase 3 data show tildrakizumab’s (Ilumya, Sun Pharma) efficacy and safety last up to five years.

According to a recent meta-analysis, patients who stop and restart biologic treatment can regain psoriasis control without experiencing unexpected safety issues.

An investigational topical phosphodiesterase (PDE)-4 inhibitor for psoriasis has demonstrated improvements on par with topical corticosteroids in phase 2b testing.

Tape strips outperformed skin biopsies by differentiating eczema from psoriasis with high accuracy, researchers report.

Using a novel autoantigen array, researchers have shown that the IgG4 anti-gliadin autoantibody might provide useful information for diagnosis and prognosis of psoriasis.

The U.S. Food and Drug Administration has approved IL-12/IL-23 inhibitor ustekinumab (Stelara, Janssen Pharmaceutical Companies of Johnson & Johnson) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6-11 years.

The European Commission has approved secukinumab (Cosentyx, Novartis) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6<18 years in the European Union.

Cath O'Niell, chief scientific officer at SkinBioTherapeutics and professor of translational dermatology at the University of Manchester, discusses her recent research on developing probiotics to treat psoriasis and other inflammatory skin diseases.

Studies offer further insight into risks associated with biologic therapy. One study suggests it’s not necessary to stop biologic therapy preoperatively to limit post-operative infections. Another systematic review does not rule out melanoma risk.

The U.S. Food and Drug Administration has approved Wynzora Cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%, MC2 Therapeutics) for adult with plaque psoriasis. Wynzora is equipped with the MC2 Therapeutics’ patented PAD Technology and is currently under review in the EU.

Guselkumab becomes the first IL-23 inhibitor approved for treatment of psoriatic arthritis by the U.S. Food and Drug Administration (FDA) following positive phase 3 results from two trials investigating the safety and efficacy of the drug.

The U.S. Food and Drug Administration has approved Mylan and Fujifilm Kyowa Kirin Biologics’ adalimumab-fkjp as a biosimilar to AbbVie’s adalimumab for a variety of inflammatory disease including plaque psoriasis and psoriatic arthritis.

A recently published review offers early insight into the risk and prognosis of COVID-19 in individuals receiving biologic therapy, providing recommendations for patient care and counseling.

Treatment with biologics may worsen infection risk, not prognosis, according to findings from a case-control study comprised of more than 10 million residents of the Lombardia region of Italy.

Case study finds no safety concerns, suggests possible benefit of apremilast for countering COVID-19 virus-induced inflammation.

Dermavant announces the enrollment completion for their long-term safety study investigating tapinarof in adults with plaque psoriasis as a part of the PSOARING 1 and PSOARING 2 phase 3 program.

AbbVie announces they have filed applications with the U.S. FDA and EMA for the approval of the JAK inhibitor upadacitinib for the treatment of adult active psoriatic arthritis.

Dermavant announces the publication of their phase 2b clinical trial investigating tapinarof cream for the treatment of adult plaque psoriasis in The Journal of the American Academy of Dermatology (JAAD).